Skip to main content
Assets
AstraZeneca logo
AZN.LSE
AstraZeneca
Health Care · Pharmaceuticals

British-Swedish multinational pharmaceutical and biotechnology company developing treatments for cancer, cardiovascular, and respiratory diseases.

HQ: United KingdomListed: United Kingdom

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for AstraZeneca.

Historical AI ConsensusHistorical AI Forecasts

AstraZeneca plc (AZN.LSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 June 2026Deep analysis 5 June 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Elon Musk AI advisor icon

Elon Musk AI

The Visionary FrameworkAI Thinker

Model rating

Buy

5-Year Return Est.

+88.8%

Includes 0.02% annual net dividend contribution

1. Investment Thesis — Base Case

AstraZeneca is mathematically poised to dominate the biotech . I strongly believe the baseline physics of their , paired with their staggering $14 billion R&D data engine, ensures they will successfully transition into a fast-adopting generative-biology powerhouse. Over the 5-year horizon, legacy patent cliffs will generate temporary friction, but relentless cash generation and accelerated AI pipeline velocity will violently overwhelm those drags. The company crosses the threshold where their structural permanently expands, leaving legacy competitors behind.

  • integrations collapse wet-lab R&D cycles by 30% to 50%.
  • Enhertu and broader ADC dominance secure in oncology.
  • Massive $9B+ seamlessly funds bolt-on frontier biotech acquisitions.
  • Macro volatility drives a sustained bid into high-margin, IP-backed defensive moats.
  • Global demographic aging mathematically forces regardless of cycle.
  • The implied capitalization is highly rational given the structural shift in life-science economics.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.6.19K11.48K16.76K22.04K27.33KJun 2021Dec 2023Jun 2026Dec 2028Jun 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (GBX)
Observed price2021-06-017,955
Observed price2021-06-258,478
Observed price2021-07-038,765
Observed price2021-07-238,417
Observed price2021-08-088,232
Observed price2021-08-208,708
Observed price2021-08-248,589
Observed price2021-09-178,063
Observed price2021-09-258,618
Observed price2021-10-119,003
Observed price2021-10-198,739
Observed price2021-11-049,443
Observed price2021-11-168,602
Observed price2021-12-108,193
Observed price2021-12-148,228
Observed price2021-12-308,673
Observed price2022-01-198,785
Observed price2022-02-048,356
Observed price2022-02-088,356
Observed price2022-02-289,167
Observed price2022-03-088,886
Observed price2022-04-0110,135
Observed price2022-04-0510,302
Observed price2022-04-0910,824
Observed price2022-05-0310,684
Observed price2022-05-1110,026
Observed price2022-06-169,760
Observed price2022-06-2410,776
Observed price2022-07-1011,104
Observed price2022-07-2210,766
Observed price2022-08-1110,506
Observed price2022-08-1911,250
Observed price2022-08-2711,241
Observed price2022-09-1610,119
Observed price2022-09-2810,076
Observed price2022-10-149,818
Observed price2022-10-229,719
Observed price2022-11-0310,682
Observed price2022-11-1510,800
Observed price2022-12-0911,354
Observed price2022-12-1711,234
Observed price2023-01-0611,717
Observed price2023-01-1011,685
Observed price2023-02-0310,333
Observed price2023-02-0710,666
Observed price2023-02-1911,496
Observed price2023-03-1110,695
Observed price2023-03-3111,192
Observed price2023-04-0411,432
Observed price2023-04-2412,267
Observed price2023-05-2212,028
Observed price2023-05-2611,613
Observed price2023-06-0711,754
Observed price2023-06-2311,422
Observed price2023-06-2711,190
Observed price2023-07-0910,096
Observed price2023-08-1011,162
Observed price2023-08-1810,658
Observed price2023-09-0310,683
Observed price2023-09-1510,793
Observed price2023-09-1910,839
Observed price2023-09-2711,085
Observed price2023-10-1710,792
Observed price2023-11-0610,240
Observed price2023-11-1810,243
Observed price2023-11-2610,026
Observed price2023-12-1610,226
Observed price2024-01-0510,758
Observed price2024-01-0910,902
Observed price2024-02-0210,360
Observed price2024-02-0610,534
Observed price2024-02-109,662
Observed price2024-03-0510,112
Observed price2024-03-2910,696
Observed price2024-04-0210,604
Observed price2024-04-2611,988
Observed price2024-04-3012,062
Observed price2024-05-2412,329
Observed price2024-05-2812,028
Observed price2024-06-0512,516
Observed price2024-06-2512,550
Observed price2024-07-0712,000
Observed price2024-07-2312,190
Observed price2024-08-1613,046
Observed price2024-09-0113,276
Observed price2024-09-1312,042
Observed price2024-09-1711,936
Observed price2024-09-2911,621
Observed price2024-10-1511,980
Observed price2024-11-089,790
Observed price2024-11-169,990
Observed price2024-12-0210,746
Observed price2024-12-1010,620
Observed price2024-12-1810,375
Observed price2025-01-1510,648
Observed price2025-01-3111,344
Observed price2025-02-0411,030
Observed price2025-02-2811,968
Observed price2025-03-0412,064
Observed price2025-03-2811,416
Observed price2025-04-0111,366
Observed price2025-04-099,667
Observed price2025-05-0310,645
Observed price2025-05-1510,176
Observed price2025-06-1211,030
Observed price2025-06-2010,392
Observed price2025-06-2810,132
Observed price2025-07-1410,662
Observed price2025-07-2210,352
Observed price2025-08-1511,592
Observed price2025-08-1911,782
Observed price2025-09-0412,150
Observed price2025-09-2811,055
Observed price2025-10-1012,886
Observed price2025-10-2212,485
Observed price2025-11-0712,907
Observed price2025-11-1113,322
Observed price2025-11-2714,061
Observed price2025-12-1313,460
Observed price2025-12-2913,737
Observed price2026-01-1414,346
Observed price2026-01-2213,560
Observed price2026-02-0313,816
Observed price2026-02-2715,542
Observed price2026-03-0314,932
Observed price2026-03-2313,742
Observed price2026-04-0415,283
Observed price2026-04-2413,956
Observed price2026-05-0613,322
Observed price2026-05-2213,997
Observed price2026-05-2613,960
Observed price2026-06-1513,200
Observed price2026-07-0514,219
Observed price2026-07-1712,594
Observed price2026-07-2913,134
Observed price2026-08-1411,460
Observed price2026-08-2612,234
Observed price2026-09-1111,708
Observed price2026-09-1512,116
Observed price2026-09-1812,500
Published advisor forecast2026-06-0413,554
Published advisor forecast2026-09-0414,096
Published advisor forecast2026-12-0414,519
Published advisor forecast2027-03-0415,245
Published advisor forecast2027-06-0414,940
Published advisor forecast2027-09-0415,538
Published advisor forecast2027-12-0416,470
Published advisor forecast2028-03-0416,964
Published advisor forecast2028-06-0417,303
Published advisor forecast2028-09-0417,130
Published advisor forecast2028-12-0417,987
Published advisor forecast2029-03-0419,066
Published advisor forecast2029-06-0419,829
Published advisor forecast2029-09-0420,820
Published advisor forecast2029-12-0421,653
Published advisor forecast2030-03-0422,303
Published advisor forecast2030-06-0421,856
Published advisor forecast2030-09-0422,949
Published advisor forecast2030-12-0423,867
Published advisor forecast2031-03-0424,822
Published advisor forecast2031-06-0425,567

2. Scenarios & Signals

Bull case

The frontier physics holds true, and AZN evolves into a true paradigm shifter. If in-vivo CRISPR therapeutics and AI-native drug design yield unprecedented clinical success without safety blowups, AZN transcends pharma entirely.

  • AI drug-discovery platforms yield blockbuster therapeutics in record time.
  • Oncology effectively rewrite standard-of-care across multiple solid tumors.
  • Unrestricted data scaling creates an insurmountable computational biology moat.
  • The market entirely reprices AZN as a high-growth tech platform rather than a legacy drugmaker.

Bear case

The fundamental physics of their next-gen pipeline hits a biological wall, exposing AZN as an overvalued narrative trap. If computational models fail to translate to complex human in-vivo systems, the massive R&D spend becomes dead weight.

  • Massive Phase III failure in next-gen due to systemic toxicity.
  • brutally amputates the China revenue engine.
  • AI investments prove to be a cash-incinerating mirage that fails to improve FDA approval odds.
  • Patent cliffs arrive faster than new revenues can bridge the gap, crushing margins.

Current crowd narrative

The crowd views AstraZeneca as a high-quality, defensively positioned European pharmaceutical major navigating patent cliffs via a solid . Sell-side models obsess over the quarter-to-quarter sales of Enhertu and Farxiga, treating the company as a traditional chemical-molecule manufacturer. The consensus trades AZN as a safe-haven dividend stock with moderate upside, totally anchored to historical P/E multiples and incremental pipeline probability weightings.

Alpha-gap assessment

The is profound: Wall Street is pricing AstraZeneca based on trailing pharmaceutical economics, completely ignoring the information-theoretic underway. AZN is not a drug company; it is an emerging biological data-refinery. By applying massive compute and AI to their $14 billion R&D budget, they are on the verge of structurally collapsing the time and cost required to discover and validate therapeutics. The is the market's inability to price exponential ; when clinical trial failure rates plummet due to in-silico modeling, the structural ceiling of this entire enterprise shifts higher permanently.

Convergence catalyst

The convergence will trigger when AZN delivers a major FDA approval for a drug discovered and validated end-to-end via AI/computational platforms in less than half the historical industry time. This single data point will mathematically force the market to reprice AZN's entire future R&D pipeline.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus